Expressions of CK-19, NF-κB, E-cadherin,-βcatenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma

Journal of Experimental Therapeutics and Oncology

Volumn 9, Issue 3, 2011, Pages 187-199

  Sethi, Kruttibas ^a   Sarkar, Siddik ^a   Das, Subhasis ^a   Rajput, Shashi ^a   Mazumder, Abhijit ^c   Roy, Bhaskar ^a   Patra, Susmita ^d   Mohanty, Biswanarayan ^b   El Naggar, Adel K ^c   Mandal, Mahitosh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

^b S C B MEDICAL COLLEGE   (India)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NONE

Author keywords

catenin; Cytokeratin 19 (CK 19); Differentiated thyroid carcinoma (DTC); E cadherin; Follicular thyroid carcinoma (FTC); Nuclear factor kappa B (NF B); Papillary thyroid carcinoma (PTC)

Indexed keywords

BETA CATENIN; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UVOMORULIN;

ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER INVASION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFERENTIATED THYROID CANCER; GOITER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID TUMOR;

BETA CATENIN; CADHERINS; CARCINOMA, PAPILLARY; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; NF-KAPPA B; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84455171494     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Chen H, Nicol TL & Udelsman R. Follicular lesions of the thyroid. Does frozen section evaluation alter operative management? Ann Surg 222: 101-106, 1995.
2. Nasr MR, Mukhopadhyay S, Zhang S & Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol 19: 1631-1637, 2006. (Pubitemid 44789932)
3. de Micco C, Savchenko V, Giorgi R, Sebag F & Henry JF. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer 98: 818-823, 2008. (Pubitemid 351272603)
4. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A & Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18: 48-57, 2005. (Pubitemid 40128094)
5. Rorive S, Eddafali B, Fernandez S, Decaestecker C, Andre S, Kaltner H, Kuwabara I, Liu FT, Gabius HJ, Kiss R & Salmon I. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol 15: 1294-1301, 2002. (Pubitemid 35462997)
6. Cheung CC, Ezzat S, Freeman JL, Rosen IB & Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14: 338-342, 2001). (Pubitemid 32298919)
7. Ghosh S, May MJ & Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16, 225-260, 1998. (Pubitemid 28183365)
8. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S & Leonardi A. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279: 54610-54619, 2004. (Pubitemid 40053204)
9. Aberle H, Schwartz H & Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 61: 514-523, 1996. (Pubitemid 26240128)
10. Bracke ME, Van Roy FM & Mareel MM. The E-cadherin/ catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 213 (Pt 1): 123-161, 1996. (Pubitemid 26165088)
11. Semb H & Christofori G. The tumor-suppressor function of E-cadherin. Am J Hum Genet 63: 1588-1593, 1998. (Pubitemid 30415720)
12. Dahlman T, Grimelius L, Wallin G, Rubin K & Westermark K. Integrins in thyroid tissue: upregulation of alpha2beta1 in anaplastic thyroid carcinoma. Eur J Endocrinol 138: 104-112, 1998. (Pubitemid 28078818)
13. Naito A, Iwase H, Kuzushima T, Nakamura T & Kobayashi S. Clinical significance of E-cadherin expression in thyroid neoplasms. J Surg Oncol 76: 176-180, 2001. (Pubitemid 32240227)
14. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC & Sobrinho-Simoes M. E-cadherin loss rather than betacatenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42: 580-587, 2003. (Pubitemid 36688152)
15. Brecelj E, Frkovic Grazio S, Auersperg M & Bracko M. Prognostic value of E-cadherin expression in thyroid follicular carcinoma. Eur J Surg Oncol 31: 544-548, 2005.
16. von Wasielewski R, Rhein A, Werner M, Scheumann G.F, Dralle H, Potter E, Brabant G & Georgii A. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 57: 2501-2507, 1997.
17. Kapran Y, Ozbey N, Molvalilar S, Sencer E, Dizdaroglu F & Ozarmagan S. Immunohistochemical detection of E-cadherin, alpha- and beta-catenins in papillary thyroid carcinoma. J Endocrinol Invest 25: 578-585, 2002. (Pubitemid 34784736)
18. Kim DS. Thyroid cancer: are molecular studies making any difference?. J Laryngol Otol 121: 917-926, 2007. (Pubitemid 351650456)
19. Papotti M JR, Pompa R De, Bartolazzi A & Rosai J. Galectin-3 and HBME-1 expressionin well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Modern Pathol 18: 2005.
20. Papotti M, Rodriguez J, De Pompa R, Bartolazzi A & Rosai J. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18: 541-546, 2005. (Pubitemid 40478118)
21. Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC & Han CP. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med 7: 25, 2009.
22. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K & Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47: 391-401, 2005. (Pubitemid 41428488)
23. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, Jang HC, Park SH, Cho BY & Park SY. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 22: 621-628, 2007.
24. Laco J, Ryska A, Cap J & Celakovsky P. Expression of galectin-3, cytokeratin 19, neural cell adhesion molecule and E-cadhedrin in certain variants of papillary thyroid carcinoma. Cesk Patol 44: 103-107, 2008.
25. Zhenxian Du HZ, Daxin Gao, Huaqin Wang, Yongjun Li & Guoliang Liu. Significance of VEGF and NF-kB expression in thyroid carcinoma. Chinese Journal of Clinical Oncology 3: 2006.
26. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, & Gilks B. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. The American Journal of Surgery 191(5): 581-587, 2006.
27. Rezk S, Brynes RK, Nelson V, Thein M, Patwardhan N, Fischer A & Khan A. beta-Catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol 15: 329-337, 2004. (Pubitemid 40208913)
28. Nakashima M, Takamura N, Namba H, Saenko V, Meirmanov S, Matsumoto N, Hayashi T, Maeda S & Sekine I. RET oncogene amplification in thyroid cancer: correlations with radiationassociated and high-grade malignancy. Human Pathology 38: 621-628, 2007. (Pubitemid 46399890)
29. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL & Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158, 987-996, 2001. (Pubitemid 32221790)
30. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, Mandal M & Myers JN. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 4, 632-640, 2005. (Pubitemid 40601845)